Risk prediction for early CKD in type 2 diabetes

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 8, 2015, Pages 1371-1379

  Dunkler, Daniela ^a,b,c   Gao, Peggy ^a   Lee, Shun Fu ^a   Heinze, Georg ^c   Clase, Catherine M ^d   Tobe, Sheldon ^e   Teo, Koon K ^a,d   Gerstein, Hertzel ^a   Mann, Johannes F E ^b,f   Oberbauer, Rainer ^c,g  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MCMASTER UNIVERSITY   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f Klinikum Schwabing   (Germany)

^g Second Department of Medicine   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; RAMIPRIL; TELMISARTAN; BIOLOGICAL MARKER; CREATININE;

ADULT; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; AGED; BLOOD; DECISION SUPPORT SYSTEM; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; KIDNEY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; VALIDATION STUDY;

AGED; ALBUMINURIA; BIOMARKERS; CREATININE; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84938820753     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10321014     Document Type: Article

References (38)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908-1919, 1997
3. Taal MW: Predicting renal risk in the general population: Do we have the right formula? Clin J Am Soc Nephrol 6: 1523-1525, 2011
4. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 290: 3101-3114, 2003
5. Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 121: 293-298, 1991
6. Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, Klarenbach S; Alberta Kidney Disease Network: Population based screening for chronic kidney disease: Cost effectiveness study. BMJ 341: c5869, 2010
7. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and theircombination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant SubjectswithCardiovascularDisease (ONTARGET/TRANSCEND) trials. Am Heart J 148: 52-61, 2004
8. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008
9. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
10. Heinze G, Schemper M: Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 71: 155-163, 2003
11. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J; Origin Trial Investigators: Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: theORIGINTrial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 155: 26-32, e1-e6, 2008
12. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S; ORIGIN Trial Investigators: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.NEngl J Med 367: 309-318, 2012
13. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S; ORIGIN Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328, 2012
14. Justesen TI, Petersen JL, Ekbom P, Damm P, Mathiesen ER: Albumin-to-creatinine ratio in randomurine samplesmight replace 24-h urine collections in screening for micro- and macroalbuminuria in pregnant woman with type 1 diabetes. Diabetes Care 29: 924-925, 2006
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
16. Jardine MJ, Hata J,Woodward M, Perkovic V, Ninomiya T, Arima H, Zoungas S,Cass A, PatelA,Marre M,ManciaG, MogensenCE, Poulter N, Chalmers J; ADVANCE Collaborative Group: Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis 60: 770-778, 2012
17. Ravid M, BroshD, Ravid-SafranD, Levy Z, Rachmani R:Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158: 998-1004, 1998
18. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS StudyGroup: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55: 1832-1839, 2006
19. Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators: Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med 173: 1682-1692, 2013
20. Schmieder RE,Mann JF, SchumacherH,Gao P, ManciaG,Weber MA, McQueen M, Koon T, Yusuf S; ONTARGET Investigators: Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22: 1353-1364, 2011
21. Biesheuvel CJ, Vergouwe Y, Steyerberg EW, Grobbee DE, Moons KG: Polytomous logistic regression analysis could be applied more often in diagnostic research. J Clin Epidemiol 61: 125-134, 2008
22. Royston P, Sauerbrei W: Building multivariable regression models with continuous covariates in clinical epidemiology-with an emphasis on fractional polynomials. Methods Inf Med 44: 561- 571, 2005
23. Royston P, Sauerbrei W: Multivariable model-building. A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables, Chichester, England, John Wiley & Sons, 2008, pp 1-322
24. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54: 774-781, 2001
25. Schemper M: The relative importance of prognostic factors in studies of survival. Stat Med 12: 2377-2382, 1993
26. R Core Team: R: A language and environment for statistical computing, Vienna, Austria, R Foundation for Statistical Computing, 2013
27. O'Seaghdha CM, Lyass A, Massaro JM, Meigs JB, Coresh J, D'Agostino RB Sr, Astor BC, Fox CS: A risk score for chronic kidney disease in the general population. Am J Med 125: 270- 277, 2012
28. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, Cass A: Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: A modeled analysis. Value Health 13: 196-208, 2010
29. Echouffo-Tcheugui JB, Kengne AP: Risk models to predict chronic kidney disease and its progression: A systematic review. PLoS Med 9: e1001344, 2012
30. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J; Chronic Kidney Disease Prognosis Consortium: Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80: 93-104, 2011
31. KeaneWF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators: Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: The RENAAL study. Clin J Am Soc Nephrol 1: 761-767, 2006
32. Johnson ES, Thorp ML, Platt RW, Smith DH: Predicting the risk of dialysis and transplant among patientswith CKD: A retrospective cohort study. Am J Kidney Dis 52: 653-660, 2008
33. Hippisley-Cox J, Coupland C: Predicting the risk of chronic kidney disease in men and women in England and Wales: Prospective derivation and external validation of the QKidney Scores. BMC Fam Pract 11: 49, 2010
34. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553-1559, 2011
35. Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT; PREVEND Study Group: Development and validation of a general population renal risk score. Clin J Am Soc Nephrol 6: 1731-1738, 2011
36. Dimitrov BD, Perna A, Ruggenenti P, Remuzzi G: Predicting endstage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. Kidney Int 63: 1924-1933, 2003
37. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF; ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease): Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: A cohort study. Ann Intern Med 154: 310-318, 2011
38. Adler AI, Stevens RJ,Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232, 2003